It Seems Albany Molecular Research (NASDAQ:AMRI) Will Go Up. Just Reported Less Shorted Shares

July 26, 2017 - By Migdalia James

 It Seems Albany Molecular Research (NASDAQ:AMRI) Will Go Up. Just Reported Less Shorted Shares

Investors sentiment increased to 1.2 in 2016 Q4. Its up 0.25, from 0.95 in 2016Q3. It is positive, as 14 investors sold Albany Molecular Research, Inc. shares while 36 reduced holdings. 15 funds opened positions while 45 raised stakes. 30.62 million shares or 2.12% more from 29.98 million shares in 2016Q3 were reported.
Invesco Ltd owns 61,971 shares for 0% of their portfolio. Fisher Asset Lc owns 0% invested in Albany Molecular Research, Inc. (NASDAQ:AMRI) for 80,589 shares. Horizon Kinetics Ltd Liability reported 0.03% in Albany Molecular Research, Inc. (NASDAQ:AMRI). Nationwide Fund stated it has 16,450 shares. Ami Asset Management Corp stated it has 1.11% in Albany Molecular Research, Inc. (NASDAQ:AMRI). Moreover, Amer Group Inc has 0% invested in Albany Molecular Research, Inc. (NASDAQ:AMRI). Wells Fargo And Company Mn has 139,269 shares for 0% of their portfolio. Blackrock Fund Advsrs invested in 2.60M shares or 0.01% of the stock. Gsa Cap Ptnrs Llp has invested 0.04% in Albany Molecular Research, Inc. (NASDAQ:AMRI). Moreover, Arizona State Retirement System has 0% invested in Albany Molecular Research, Inc. (NASDAQ:AMRI). First Quadrant L P Ca owns 23,600 shares. Aperio Group Inc Ltd owns 15,420 shares or 0% of their US portfolio. Manufacturers Life Insurance The invested in 18,871 shares. Goldman Sachs Group Inc holds 0% of its portfolio in Albany Molecular Research, Inc. (NASDAQ:AMRI) for 129,955 shares. Keybank National Association Oh has invested 0% in Albany Molecular Research, Inc. (NASDAQ:AMRI).

The stock of Albany Molecular Research (NASDAQ:AMRI) registered a decrease of 10.58% in short interest. AMRI’s total short interest was 6.12M shares in July as published by FINRA. Its down 10.58% from 6.85M shares, reported previously. With 3.60M shares average volume, it will take short sellers 2 days to cover their AMRI’s short positions. The short interest to Albany Molecular Research’s float is 26.35%.

The stock decreased 0.05% or $0.01 during the last trading session, reaching $21.69. About shares traded. Albany Molecular Research, Inc. (NASDAQ:AMRI) has risen 27.56% since July 26, 2016 and is uptrending. It has outperformed by 10.86% the S&P500.

Albany Molecular Research, Inc. is a contract research and manufacturing company. The company has market cap of $931.19 million. The Firm operates through Discovery and Development Services , Active Pharmaceutical Ingredients (API), Drug Product (DP) and Fine Chemicals (FC) divisions. It currently has negative earnings. The DDS segment includes activities, such as drug lead discovery, optimization, drug development and small scale commercial manufacturing.

Albany Molecular Research, Inc. (NASDAQ:AMRI) Ratings Coverage

Among 5 analysts covering Albany Molecular (NASDAQ:AMRI), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Albany Molecular had 5 analyst reports since October 26, 2015 according to SRatingsIntel. JP Morgan downgraded the stock to “Neutral” rating in Thursday, June 8 report. The firm has “Equal-Weight” rating given on Thursday, May 11 by Morgan Stanley. As per Thursday, June 8, the company rating was downgraded by J.P. Morgan. The rating was downgraded by William Blair to “Hold” on Tuesday, June 6. The stock of Albany Molecular Research, Inc. (NASDAQ:AMRI) has “Overweight” rating given on Monday, October 26 by First Analysis.

More important recent Albany Molecular Research, Inc. (NASDAQ:AMRI) news were published by: Prnewswire.com which released: “AMRI Announces Early Termination of HSR Waiting Period for The Carlyle Group …” on June 29, 2017, also Marketwatch.com published article titled: “Albany Molecular Research to be taken private for $21.75 a share in cash”, Prnewswire.com published: “Lifshitz & Miller LLP Announces Investigation of Albany Molecular Research …” on July 03, 2017. More interesting news about Albany Molecular Research, Inc. (NASDAQ:AMRI) was released by: Globenewswire.com and their article: “The Rosen Law Firm, PA Announces Proposed Class Action Settlement on Behalf of …” with publication date: July 17, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.